Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Outpaces Other International Drug Players In High-speed Growth In China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Boosted by China's ever-expanding economy and ongoing health reforms, part of which are aimed at covering 90 percent of the country's 1.3 billion citizens with minimal medical insurance by 2011, drug firms posted an average sales growth rate of 27 percent in 2009, according to the global information provider IMS Health

You may also be interested in...



In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 2 of 2)

Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.

Sanofi Shrugs Off Price Cuts, Acquisition Risks In Emerging Markets

Like many of its competitors, Sanofi SA considers emerging markets to be its number one growth driver, as the French drug maker transforms itself from a blockbuster-dependent model to a more balanced business with less risk. The goal is to deliver sustainable continuous revenues and profits, said CEO Chris Viehbacher during a Sept. 6 strategy update session for analysts

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel